Children in Europe living with HIV are on course to receive a once-daily treatment after EU marketing authorisation (EMA) was given to ViiV Healthcare’s Triumeq PD.
The University of North Carolina at Chapel Hill and GlaxoSmithKline (GSK) are creating a new HIV research center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS.
Mylan will manufacture and distribute Gilead's antiretroviral HIV drugs, following a tech transfer, in order to increase access in developing countries.
Bristol-Myers Squibb has penned a technology transfer agreement with the Brazilian government in what it says is a bid to increase access to HIV drug Reyataz (atazanavir sulfate) in the area.
Ugandan drugs maker Quality Chemical Industries Ltd (QCIL) is ready to manufacture HIV treatment Tenofovir in a bid to dominate the local antiretroviral market.
Merck & Co.'s integrase inhibitor, the first in a new class of
HIV drug, looks likely to win approval in the near future,
following a recommendation to regulators.
It appears that pharma heavyweight Pfizer has not emerged unscathed
from the contamination chaos that has affected EU supplies of HIV
drug Viracept (nelfinavir), with the company this week warning that
its version of the treatment...
Switzerland-based Roche is helping African nations fight the AIDS
epidemic by sharing its coveted saquinavir drug-producing
technology with two more manufacturers in Ethiopia and Zimbabwe.
After a troubling few months, Pfizer has announced some good news -
US regulators have recommended its first-in-class HIV/AIDS drug
should be approved.
Under pressure to respond to the spread of HIV in the developing
world, Gilead has signed non-exclusive licence agreements with
eight Indian generic companies for the manufacture of Viread
(tenofovir disoproxil fumarate), its popular...
Researchers have theorised that a peptide found in primates could
halt the HIV-1 virus from infecting blood cells. The discovery
could form the crux of an effective drug therapy, which may
overcome resistance exhibited by current...
According to the results of a new survey HIV patients are in the
dark about treatment options and the significance of drug
resistance, not only jeopardising their own health but also
potentially exacerbating the problem of limited...
Scientists believe they have made a breakthrough in the fight
against HIV drug resistance by developing a drug that is the first
in a new class of HIV drug candidates called Maturation Inhibitors.
AIDS researchers have uncovered new evidence, which points to the
'fitness' of the HIV virus as a primary factor in explaining
different resistant patterns to the drugs that treat the disease.
A diagnostic test, which monitors anti-HIV drugs in the blood, is
set to enter development to eventually become available across
Europe. The test will be used to identify the correct dosage of
medicine for individual patients.
According to new study, the virus that causes AIDS is becoming more
sensitive to drug treatments, contradicting a wealth of research
that demonstrates the emergence of drug resistant viral strains.
A harmless virus could hold the key to the production of a more
effective HIV drug after researchers employed this virus in ongoing
studies. The research aims to outmanoeuvre the mutating nature of
the HIV virus, which has become...
An opportunity to develop drugs by targeting a recently discovered,
and potentially vulnerable, intermediate stage of the viral life
cycle, could result in a new pharmaceutical treatment in the fight
against HIV and other similar...
BioInvent become the latest company to enter the HIV/AIDS drug
arena after UK authorities gave the go ahead to commence the
company's first clinical trial of its human antibody to treat the
virus.
BioAlliance Pharma, a biopharmaceutical company focused on the
field of drug resistance may have discovered a novel way to
overcome growing HIV resistance. They have developed a new family
of integrase binding inhibitors, which...
The first documented case of drug resistant HIV has prompted calls
to step up HIV drug research after the victim developed full-blown
AIDS in just three months.
The need for an effective HIV drug became apparent as the US Food
and Drug Administration (FDA) granted Fast Track designation to the
first in a new class of HIV drugs called Maturation Inhibitors.
A new family of drugs specifically designed to inhibit nuclear
import of integrase, blocking viral replication of human
immunodeficiency virus type 1 (HIV-1) infected cells suggests an
approach that could be effective against drug...
The recent surge in HIV research shows no sign of terminating as
researchers reported the successful targeting of an HIV protein
that has eluded existing therapies. The technique used for
identifying the synthetic molecules may also...
A series of new drugs to treat HIV infection which work in
different ways to available therapies are moving through clinical
trials, raising the hope that a new generation of antivirals is on
the horizon to treat resistant strains...
The Scottish manufacturer of a safety syringe used in a new AIDS
drug has sacked most of its staff and shut down its only production
facility, but will continue to develop the technology.
